Kornimate/medical-research-clean huggingface dataset:
compare the performance of targeted biopsy versus aspiration biopsy with a pipette for the diagnosis of endometrial cancer

Conditions: Endometrial Cancer

Summary: endometrial cancer is the most common pelvic gynecological cancer in so-called developed countries, with 320,000 new cases annually, including more than 1,500 in belgium. it preferentially affects postmenopausal women. overall survival at 5 years is 76% but is 95% for early forms, which represent more than 70% of diagnoses. the main risk factors are obesity, diabetes and tamoxifen intake for breast cancer, which explains the increasing incidence. half a million new annual cases are expected in 2035. the main symptom is postmenopausal metrorrhagia.among these women, the prevalence of the disease is estimated between 10 and 15%. currently the recommendations are to make an evaluation by endovaginal ultrasound followed by an endometrial biopsy. the histological type is the main predictor of the severity of the disease and acts as guideline for the treatment.it is therefore essential to have precise biopsy results before starting therapeutic management. the most widely used technique is the blind biopsy by aspiration using a pipette because it is inexpensive, easy, without any specific equipment. however, recent studies showed that this technique has a poor sensitivity in the target population of postmenopausal women. other studies have shown that targeted biopsies under hysteroscopic control could have a much higher sensitivity. the main objective of this study is thus to compare the performance of the targeted biopsy under hysteroscopy to the performance of the biopsy by aspiration with a pipette, for the diagnosis of endometrial cancer.


Eligibility criteria:
inclusion criteria: * postmenopausal patient. * patient with postmenopausal metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result) exclusion criteria: * patients undergoing hormone replacement therapy for menopause (thm). this treatment may be the cause of benign bleeding in post menopause.

Keywords: hysteroscopy pipette biopsy endometrial cancer
study of pregabalin (lyrica) in patients with painful diabetic peripheral neuropathy

Conditions: Diabetic Neuropathy, Painful

Summary: patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. all patients will receive pregabalin, and half of patients will receive placebo at some point during the study.


Eligibility criteria:
inclusion criteria: * patients must have painful diabetic peripheral neuropathy and be receiving treatment for this condition. exclusion criteria: * patients with other pain conditions cannot participate.

Keywords: diabetic peripheral neuropathy lyrica pregabalin pain
study to evaluate the treatment effect of pt003 on cardiovascular hemodynamics in subjects with moderate to severe copd

Conditions: COPD

Summary: this is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of pt003 compared with that of placebo mdi on cardiovascular hemodynamics following chronic-dosing (7 days) in subjects with moderate to severe copd.


Eligibility criteria:
inclusion criteria: * at least 40 years of age and no older than 80 at visit 1. * women of non-child bearing potential,or negative serum pregnancy test at screening, and agrees to acceptable contraceptive methods used consistently and correctly from screening until 14 days after final visit * evidence of lung hyperinflation * subjects with an established clinical history of copd as defined by the american thoracic society (ats)/european respiratory society (ers) * current or former smokers with a history of at least 10 pack-years of cigarette smoking. * pre- and post-bronchodilator fev1/fvc ratio must be \<0.70 * post-bronchodilator fev1 must be ≥30% to \<65% predicted normal value, calculated using nhanes iii reference equations. exclusion criteria: * significant diseases or conditions other than copd which, in the opinion of the investigator, may put the patient at risk * women who are pregnant or lactating or are planning to become pregnant during the course of the study * subjects, who in the opinion of the investigator, have a current diagnosis of asthma or other active pulmonary disease * subjects who have been hospitalized due to poorly controlled copd within 3 months prior to screening * subjects who have poorly controlled copd, defined as acute worsening of copd that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to screening or during the screening period * subjects who have clinically significant uncontrolled hypertension. * subjects with symptomatic prostatic hypertrophy that is clinically significant and not adequately controlled with appropriate therapy, in the opinion of the investigator. * subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the investigator. * subjects with a calculated creatinine clearance ≤30 ml/minute using chronic kidney disease epidemiology collaboration. (ckd-epi) formula at screening and on repeat testing prior to visit 2. * subjects with abnormal liver function tests defined as ast, alt, or total bilirubin ≥ 1.5 times upper limit of normal at screening and on repeat testing prior to visit 2 * subjects who have cancer that has not been in complete remission for at least five years. * subjects with a diagnosis of glaucoma, who in the opinion of the investigator, have not been adequately treated. * subjects with a clinically significant ecg * subjects who were previously enrolled in any previous pt001, pt003, or pt005 study conducted or sponsored by pearl.
a study to evaluate whether food affects the plasma drug levels of a 35 mg single dose of pf-04447943 taken orally in healthy adult participants

Conditions: Healthy

Summary: the purpose of the study is to compare the plasma drug levels of pf-04447943 when taken as a 35 mg tablet after a high fat meal compared to when taken after fasting. healthy adult volunteers will receive a single dose of the drug once when fasted and again when fed. the safety and tolerability of the drug will be monitored.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects, not of child bearing potential. * age 18-55 inclusive * total body weight \>50 kg. exclusion criteria: * evidence or history of clinical significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic diseases * history of orthostatic blood pressure changes or orthostatic symptoms * greater than 7 drinks of alcohol per week for women and greater than 14 drinks per week for men * smoking more than 5 cigarettes per day

Keywords: pharmacokinetics, single dose, crossover, fed vs fasted state
cardiac rehabilitation in chagas heart failure

Conditions: Chagas Disease; Chagas Cardiomyopathy

Summary: due to the lack of information in the literature about the role of cardiac rehabilitation on chagas heart failure, the aim of the present study was to evaluate the effects of a cardiac exercise program on functional capacity, cardiac function, respiratory muscle strength, body composition, biomarkers and quality of life among chagas heart failure patients.

the present study consisted in a pre/post single-arm intervention study conducted at the evandro chagas national institute of infectious disease (ini), located on rio de janeiro, brazil. ini is a national reference center for treatment and research in infectious diseases and tropical medicine in brazil, which follows a large cohort of patients with chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). patients included in the study were submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during an 8-month period. nutritional and pharmaceutical counseling were also monthly provided during the follow-up and consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.patients included in the study were followed during an 8-month period in which evaluations of functional capacity (maximal progressive cardiopulmonary exercise test), muscle respiratory strength (manovacuometry) and body composition (anthropometry and skinfolds) were performed at baseline, after four months and at the end of follow-up. assessments of cardiac function (bidimensional echocardiography), biomarkers (lipid profile, glucose and glycated hemoglobin) and quality of life (minnesota living with heart failure questionnaire) were taken at baseline and after eight months of follow-up.

Eligibility criteria:
inclusion criteria: * patients at the stages c or d of chagas cardiomyopathy * patients receiving standard optimized medical therapy * patients with good adherence to outpatient treatment within the last three months. exclusion criteria: * those who were not able to attend three weekly training sessions, * those who had neuromuscular limitations, cardiopathies from non-chagasic etiology (e.g ischemic), systemic conditions that limits exercise practice (e.g chronic obstructive pulmonary disease) * practitioners of regular exercise.
effect of tu-100 in patients undergoing laparoscopic colectomy

Conditions: Postoperative Ileus

Summary: tu-100 is a gastrointestinal drug produced from the three botanical raw materials, asian ginseng, zanthoxylum fruit (japanese pepper), and ginger, based on proprietary aqueous decoction and granulation technology. the aim of this study is to assess the effect of tu-100 on post-operative quality of life during the 4 week postoperative period after straight, hand-assisted, or robot-assisted laparoscopic colectomy. optimal efficacy parameters for subsequent outcome studies also will be explored.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * has a current diagnosis of colon cancer, diverticulitis, or benign colonic neoplasm * requires straight, hand-assisted, or robot-assisted laparoscopic colectomy * requires hospitalization for surgery and recovery exclusion criteria: * has been diagnosed with rectal cancer, advanced or metastatic colon cancer, crohn disease, ulcerative colitis, or volvulus * requires resection of rectal lesion * has received or is scheduled to receive chemotherapy during the duration of the study * is a pregnant or lactating female * has diabetic neuropathy * has a history or presence of diabetic gastroparesis * has a compromised immune system, either from treatment with corticosteroids or other immunosuppressive agent within 2 weeks of surgery or from immunosuppressive disease (e.g., human immunodeficiency virus) * has any other serious condition that might adversely affect suitability for participation in this study, such as liver disorder (including alanine aminotransferase or aspartate aminotransferase level greater than 2.5 times the upper limit of normal), kidney disorders, heart failure, blood disorders, or metabolic disorders * has a history or presence of interstitial pneumonia * has a history of allergic reaction to ginseng, ginger or zanthoxylum fruit (japanese pepper) * plans to receive any abdominal irradiation * is clinically lactose intolerant

Keywords: gastrointestinal quality of life index (giqli) postoperative quality of life abdominal bloating laparoscopic colectomy postoperative ileus (poi)
role of heparin in poor responders undergoing in vitro fertilisation

Conditions: Infertility

Summary: the addition of heparin increases pregnancy outcome parameters in poor responders undergoing in vitro fertilisation (ivf)


Eligibility criteria:
inclusion criteria: * poor responders (age\>40, abnormal ovarian test, \</=4 oocytes in previous cycle with conventional stimulation) * infertility, indication for ivf * no contraindications for heparin

Keywords: in vitro fertilisation poor responders
the effectiveness of short-term massage versus trabert current therapy in patients with low back pain

Conditions: Low Back Pain

Summary: background: low back pain (lbp) is still a frequent health problem. recurrance of symptoms leads to high absence at work. it was proved in previous studies that low back manual massage has a significant impact on pain reduction. trabert current (tc) is common physical modality used in rehabilitation of patients with lbp. the aim of study was to assess the effectiveness of manual massage in comparison to tc in patients with lbp. methods: sixty patients with lbp were enrolled in to the study. in all patients discopathy and spondyloarthrosis were diagnosed. the subjects were randomly assigned to two groups: massage (i=30) and tc (ii=30) therapy. the procedures were performed for ten days. pain intensity was assessed by numerical rating scale. quality of life and the degree of disability were evaluated by oswestry disability index and roland-morris disability questionnaire. results: in both groups pain reduction and functional improvement were observed after therapy. however, better results were noticed in group i.


Eligibility criteria:
inclusion criteria: * confirmed in x-ray spondyloarthrotic changes in lumbar area of spine * pain of lumbar area lasting than 1 year exclusion criteria: * cardiac rythm disturbances * cardiac pacemaker * heart failure * pulmonary embolism * atherosclerosis * neoplasmatic diseases * skin lesions or purulent changes in the area of procedure * pregnancy * advanced osteoporosis * spine fractures * fever

Keywords: massage low back pain trabert current ultra-reiz current
community health navigator program to promote cancer screenings among ddbhh people

Conditions: Cancer; Deafness

Summary: intervention to promote cancer screenings among deaf, deafblind, and hard of hearing participants who have not received screening within the recommended guideline.

study hypothesizes that the intervention that involves utilization of a ddbhh chn will result in (i) ddbhh patients demonstrating greater adherence to screening compared to ddbhh patients who were assigned to the standard of care group , and (ii) higher patient-physician communication rating by ddbhh patients compared to ddbhh patients who were assigned to the standard of care group. bilingual asl-english measures (e.g., sociodemographics, cancer knowledge, patient-physician communication) will be administered to the participant at baseline data collection and again after the final data collection or by 11 months for comparison.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form stated willingness to comply with all study procedures and lifestyle considerations (see section 5.3, lifestyle considerations) and availability for the duration of the study male or female at birth age 45-80yo or female at birth age 45-80yo; age-eligible according to screening criteria self-reported diagnosis of bilateral hearing loss at birth or prior to 13 years old (defined as "early deafness") and use asl willingness to adhere to the chn clinical trial regimen willingness to provide cancer screening verification documentation; this will be reviewed during the informed consent procedure access to necessary resources to support video-based communication non-adherent to one or more cancer screening guidelines for breast, lung, prostate, colon, cervical cancers will be those who reported not having had the appropriate recommended screenings within the past year to cancer screening questions in the hints-asl survey exclusion criteria: * presence of full ability to hear in one or both ears beyond 13 years of age younger or older than the age cutoff for the recommended cancer screening not capable of independently conducting the activities of daily living in compliance with age- or risk-specific screening at the time of evaluation for study eligibility are currently undergoing cancer treatment or being evaluated for the presence of cancer at the time of evaluation for study eligibility will be engaged in more than 21 consecutive days of travel during the eleven-month study window knows other participants at baseline
the effect of unfavorable histological features on the oncological outcomes of colon cancer

Conditions: Colon Cancer

Summary: to explore the effect of unfavorable histological features on the clinical outcomes of patients receiving radical resection of colon cancer.


Eligibility criteria:
inclusion criteria: 1. age: 18-100 years old; 2. postoperative pathology confirmed colon adenocarcinoma; 3. the tumor is located from the cecum to the sigmoid colon; 4. no distant organ metastasis; exclusion criteria: 1. simultaneous or metachronous multiple primary colorectal cancer; 2. history of previous malignant tumors (except for completely cured cervical carcinoma in situ or basal cell carcinoma or squamous epithelial skin cancer) 3. local excision procedure; 4. palliative resection (r2 resection); 5. pregnant or lactating women.
comparison of the effects of whole body vibration training and aerobic exercise on premanstrual syndrome

Conditions: Exercise; Whole Body Vibration

Summary: aim: the aim of the study was to compare the effects of whole body vibration training (wbvt) and aerobic exercise on premenstrual syndrome in young women with routine dietary intake.

methods: a prospective, randomised, pre-post-test, single-blind, controlled study was conducted in 34 women diagnosed with pms. participants were randomly assigned into three groups: the aerobic exercise group (aeg, n=11), the whole-body vibration training group (wbvt, n=11), and the control group (cg, n=12). participants in the aeg performed 45-minute exercise sessions (10 minutes warm-up, 30 minutes walk, 5 minutes cool down) three times a week for eight weeks. the wbv program was conducted using a 25 hz frequency and a 2 mm low amplitude on the power plate® (pro5tm) machine, which provides three-plane oscillatory motion. the program lasted eight weeks, with sessions held three days a week, ensuring at least one rest day between sessions. the control group was asked to continue their daily life routines. dietary intake of all participants was monitored, and those with different diets were excluded from the study. premenstrual syndrome questionnaire (pmss) was used to evaluate pms symptoms and visual analogue scale (vas) was used to evaluate pain.

Eligibility criteria:
inclusion criteria: * bmi between 18.5-25 * score over 110 points on the pms questionnaire * to be between the ages of 18-35 * sedentary women * having a regular menstrual cycle (24-35 days) exclusion criteria: * diagnosed with eating disorder * taking nutritional supplements before the last three cycles * dm, thyroid and liver kidney disorders * endocrine drug use * has undergone orthopedic surgery within the last 6 months * with a neurological diagnosis * with limited range of motion * diagnosed with cardiovascular and cardiopulmonary system disorders * diagnosed with women's health and diseases such as polycystic ovary syndrome, endometriosis * oral contraceptive users * psychiatric diagnosis * smoking * diagnosed with amenorrhea * following a regular diet * during pregnancy and lactation

Keywords: whole body vibration exercise premanstrual syndrome
effect of pilates exercises on gross motor function and balance

Conditions: to Determine the Effect of Pilate's Exercises on Gross Motor Function and Balance

Summary: the study aimed to asses the effect of pilate exercise on motor function and balance in diplegic children


Eligibility criteria:
inclusion criteria: * 7 to 9 years, * mild spasticity of lower limb * able to understand and follow instructions exclusion criteria: * fixed contracture * visual or respiratory disorders,
macrophage programing in acute lung injury

Conditions: Acute Respiratory Distress Syndrome

Summary: the histologic hallmarks of lung inflammation and in the extreme, acute respiratory distress syndrome (ards), include intense accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. macrophages are key players in all of these. here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).


Eligibility criteria:
inclusion criteria: 1. written, informed consent (by surrogate if unconscious or if altered mental status) 2. admission to a medical intensive care unit 3. orally/nasally intubated, evaluable within 24 h of intubation or onset of ards 4. expected to remain mechanically ventilated for at least 48 h after the first study procedure. exclusion criteria: 1. treatment with immunosuppressants in the prior 3 months (antineoplastic agents, tumor necrosis factor alpha antagonists, cyclosporine, methotrexate, azathioprine, or mycophenolate. treatment with glucocorticoids for septic shock is acceptable). 2. history of solid organ or bone marrow transplantation 3. history of chronic lung disease (e.g. copd, pulmonary fibrosis, cystic fibrosis) 4. human immunodeficiency virus positivity 5. severe or massive hemoptysis 6. at significant risk for bleeding (inr \> 3 or ptt \> 3x normal) 7. presence of an advanced directive to withhold life-sustaining treatment 8. morbid state or expected to survive less than 14 days because of an advanced co-morbid medical condition; 9. pregnancy
effects of mucoprotective product on xerostomia

Conditions: Xerostomia

Summary: in the present study with a randomized, cross-over, blind, placebo controlled design, the effects of a salivary substitute product and a new mucoprotective product with similar mechanisms of action but with different composition and characteristics will be evaluated in cancer patients suffering from xerostomia.


Eligibility criteria:
inclusion criteria: 1. the patient must be at least 18 years of age. 2. the patient must have clinical symptoms of xerostomia (dry mouth) due to treatment of head and neck cancer 3. the patient must understand and consent in writing to the procedure. exclusion criteria: 1. do not meet the criterion for "dry mouth" regarding saliva secretion threshold values. 2. known allergy to ingredients in the products to be used in the trial and/or allergy to soy, peanuts, citrus fruit,yerba santa or methyl parabene 3. patients who are unable or unwilling to cooperate with study procedures.

Keywords: xerostomia, saliva, mucoprotection, oral health